Cronos Group Inc vs T Rowe Price Group Inc — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while T Rowe Price Group Inc trades at $104.25 (market cap $22.23B). The key difference: T Rowe Price Group Inc is far larger — about 18.8× Cronos Group Inc's market cap, and T Rowe Price Group Inc pays a 4.99% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and T Rowe Price Group Inc for 115 Days on average.
| CRON | TROW | |
|---|---|---|
Market Cap | $1.18B | $22.23B |
Volume | 968,037 | 2,834,949 |
Sector | Health | Financials |
52-Week High | $3.55 | $121.68 |
52-Week Low | $2.30 | $86.19 |
Typical Hold Time | 22 Days | 115 Days |
Enterprise Value | $387.62M | $19.43B |
Dividend Yield | — | 4.99% |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.24, down 1.37% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $9.45M in 2025 despite revenue growth to $146.59M, but recent quarters show earnings beats. Analyst sentiment is mixed with 20% buy, 60% hold, and 20% sell ratings. Recent news highlights investor day events and international expansion efforts.
The outlook is cautious; profitability improvements and cash flow generation are key catalysts, but high valuation multiples and negative net cash flow pose risks. Regulatory developments in cannabis markets and execution on growth targets will be critical for stock performance.
T. Rowe Price Group (TROW) trades at $104.07, up 0.45% with bearish technical signals but strong fundamentals including a 10.45 P/E ratio and 29.26% net margin. Recent earnings beat expectations in Q1 and Q2 2026, while Q4 2025 slightly missed. The company maintains robust cash flow with $704.4M net cash flow in 2025 and a dividend yield near 5% with 40 years of consecutive growth.
The stock offers value with attractive valuation metrics and consistent profitability, though technical indicators suggest near-term pressure. Key risks include market-sensitive revenue streams and net outflows, while analyst consensus at $112 target implies 7.6% upside potential from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →